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CT numbers, thus demonstrating the need for CBCT 
corrections as investigated in this work. The DIR inaccurately 
matches the outline of the bladder (see dashed circle), 
leading to a wrong anatomy in the vCT. In contrast, the 
CBCTcor bladder anatomy agrees well with the original CBCT.  
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Its excellent soft tissue contrast makes MRI extremely well 
suited for guidance of external beam radiotherapy.  
In recent years, using cone beam CT-linac radiotherapy 
systems, great success has been realized in the minimal 
invasive treatment of prostate tumours, stereotactic ablative 
body radiotherapy of lung tumours and stereotactic 
treatment of tumours of the brain. For these tumours, there 
is good visualization of the tumour itself or there is a good 
visualization of tumour related structures or fiducial markers. 
There is a clear trend towards better targeting with less 
normal tissue involvement and thus less toxicity, less surgery 
and less fractionation. However, for most other tumour 
locations the limited visualization using cone beam CT and 
the lack of dynamic information hinders this development. 
On-line and real-time MRI guidance may offer the possibility 
to implemented this stereotactic revolution for most 
remaining tumour locations like radiotherapy of tumours of 
the rectum, oesophagus, pancreas, kidney, individual lymph 
nodes, etc. This may provide a breakthrough in the 
application of radiotherapy and redefine the relation 
radiotherapy and surgery.  
Essential is the availability of high quality MRI (e.g.1.5T 
Philips Ingenia) during the actual treatment process. The 
design of the experimental UMCUtrecht/Elekta MRI-Linac 
combination has been described in Lagendijk et al. [2008] 
and Raaymakers et al. (2009). The MRI accelerator facilitates 
good soft tissue visualization and continuous patient anatomy 
updates regarding translations, rotations and deformations of 
targets and organs at risk. Accounting for this, demands high 
speed, online intensity-modulated radiotherapy re-
optimization. The MRI must supply real-time information 
about the actual position of the tumour and organs at risk 
and the on-line treatment planning must be able to deal with 
this. Dedicated sequences and correction protocols are being 
developed to guarantee extreme fast and geometrically 
correct MR imaging. Essential is that the complete 3D 
anatomy can be followed in real-time. Treatment planning 
procedures are being developed which can optimize the dose 
delivered on the actual anatomy. 
The radiation dose is being delivered with the patient in a 
1.5T magnetic field. The actual dose deposition, beam 
characteristics and absolute dosimetry must be evaluated for 
this magnetic field environment. 
The clinical introduction of the MRL system is being 
organized within an international consortium. Within this 
consortium structure imaging protocols are being optimizes, 
‘blue sky’ approached are being discussed for several tumour 
groups and the actual clinical trials are being designed. 
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Current status of particle therapy in the Netherlands 
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In 2009, the Health Council of Ministry of Health published 
the Horizon Scanning Report Proton Radiotherapy, which 
paved the way for the clinical introduction of proton therapy 
in the Netherlands. In this report, four categories of 
indications were identified, including: standard indications 
(e.g. pediatric patients), prevention of secondary tumors in 
young patients with favorable prognosis (e.g. Hodgkin 
lymphoma), potential indications (i.e. dose escalation 
without enhancing toxicity) and the model-based indications 
(i.e. prevention of side effects). The model-based indications 
are the largest group of indications. In this category, patients 
will only be selected for proton therapy after an individual 
planning comparison and if the difference in dose translates 
in a minimal difference in NTCP (ΔNTCP). This model-based 
approach has been recognized by the Health Insurance Board 
as well, which means that patients selected for proton 
therapy according to this approach will receive 
reimbursement for their treatment. 
In addition to this, the Ministry of Health, together with the 
proton therapy initiatives launched a national plan for proton 
therapy, which includes the realization of four small to 
medium sized proton therapy centers, with a geographic 
distribution over the country that foresees optimal 
accessibility of proton therapy for all eligible patients in the 
Netherlands. The maximum capacity to be created is 2,200 
patients per year, divided among these four centers. These 
centers are now under construction. 
Consensus has been reached on a national level regarding the 
threshold for ΔNTCP to be selected for proton therapy. More 
detailed indication protocols are now developed coordinated 
by the National Proton Therapy Platform, in which all 
radiotherapy departments are represented.  
In addition, the four initiatives closely collaborate to create 
a national prospective data registry program to create a 
rapid learning health care system which can be used to 
develop and externally validate NTCP-models and to validate 
the added value of proton therapy to reduce radiation-
induced side effects. 
In this way, the Netherlands is one of the first countries 
worldwide that will realize a well balanced national plan for 
proton therapy in which this new technology will be 
integrated in a multicenter clinical research environment.  
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Purpose: In 2005, the word “theranostics” was used for the 
first time for describing the use of imaging for therapy 
planning in radiation oncology. It is defined as the use of 
individual patient-level biological information in choosing the 
optimal therapy for that individual [1]. In Nuclear Medicine 
this term describes the use of short-lived tracers for 
predicting the absorbed doses in molecular radiotherapy and, 
thus, safety and efficacy of a treatment. 
Materials/Methods: For pre-therapeutic dosimetry for the 
purpose of dose-planning or for post-therapeutic dose 
verification, quantitative imaging of the biokinetics of the 
administered radiolabelled substance is necessary followed 
by the calculation of the absorbed doses with potential 
inclusion of biological effects. This comprises the following 
three steps: 
a) Quantitative Imaging 
The established method for quantitative imaging for 
dosimetry relies on the measurement of the biokinetics 
by serial PET/CT, SPECT/CT or whole body scan. For 
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quantification the proper attenuation, scatter and 
partial volume corrections need to be applied. If organ 
or lesion dosimetry is performed, precise determination 
of organ/lesion volumes is necessary. Care has to be 
taken for an appropriate calibration of the imaging 
system. 
b) Biokinetics 
  This requires the determination of a correct temporal 
sampling and the use of ad hoc procedures to integrate 
the activity within time to obtain the total number of 
decays occurring in the source organs and thus the 
time-integrated activity coefficients (TIACs). 
c) Absorbed dose Calculation 
If the TIACs of the relevant structures are known, a 
calculation of the absorbed doses can be performed by 
applying, in most cases, the “MIRD formalism”: 
D = Ã*S 
D: the mean absorbed dose to a voxel or a target 
region from the cumulated activity in a source region. 
Ã: the cumulated activity (i.e. the integral of the 
time-activity curve) 
S: S factor (= mean absorbed dose per unit cumulated 
activity in the voxel or the target region).  
Different dose calculation approaches exist: These may 
either be based on tabulated S factors (with mass correction) 
of anthropomorphic phantoms, on convolution kernels or on 
Monte-Carlo simulations. 
Results: The most successful pairs of isotopes for theranostics 
are I-123/I-124/I-131 [2] and Ga-68/Lu-177/Y-90 [3]. In 
addition, Y-90 PET/CT provides a good estimate of the 
absorbed doses in selective internal radiotherapy for loco-
regional liver treatment [4]. 
 
Conclusion: Although many new radiopharmaceuticals are 
available for imaging and molecular radiotherapy it is still a 
challenge to establish reliable dose-response relationships.  
 
Keywords: Molecular radiotherapy, quantitative imaging, 
absorbed dose calculation 
 
References: 
[1] Bentzen SM. Lancet Oncol. 2005;6:112–7. 
[2] Luster et al. EJNMMI. 2008;35:1941-59 
[3] Bodei et al. EJNMMI. 2013;40:800-16 
[4] Lhommel et al. EJNMMI. 2009;36:1696 
 
134 
Single-cell S-value calculations for Auger-electron emitting 
radionuclides 
B.Q. Lee1, N. Falzone2,3, J.M. Fernández-Varea4, K.A. Vallis2, 
A.E. Stuchbery1, T. Kibédi1 
1 (Australian National University, Canberra, Australia)   
2 (University of Oxford, Oxford, United Kingdom) 
3 (Tshwane University of Technology, Pretoria, South Africa) 
4 (Universitat de Barcelona, Barcelona, Spain) 
 
Purpose: Auger-electron (AE) emitting radionuclides could be 
exploited for therapeutic purposes due to the high local 
energy deposition by low-energy Auger electrons or may 
deliver an unintentional mean absorbed dose burden when 
used as medical imaging agents. The aim of this study is to 
provide S-values for selected 14 AE emitting radionuclides 
based on the latest radiation spectra.  
Methods: The Monte Carlo code PENELOPE [1] was used to 
transport the complete radiation spectra of 67Ga, 80mBr, 89Zr, 
90Nb, 99mTc, 111In, 117mSn, 119Sb, 123I, 124I, 125I, 135La, 195mPt and 
201Tl using the methodology described in Ref. [2]. Radiation 
spectra was based on the unabridged nuclear decay data 
from MIRD RADTABS program [3] and the radiation spectra 
generated using the BrIccEmis code [4]. Taking the nucleus as 
the target, simulations were run assuming uniformly 
distributed activity in the nucleus (N←N), in the cytoplasm 
(N←Cy) or on the cell surface (N←CS).  
Results: A comparison of calculated Auger yields for all 14 
radionuclides is shown in the table below. Auger yields from 
MIRD are consistently higher than the values calculated using 
the BrIccEmis code. The methodology used to produce data 
in MIRD did not account for variations in binding energies 
during atomic relaxation thus overestimated the intensity of 
low-energy electrons.  
 
BrIccEmiss determined S-values were generally lower 
compared with MIRD S-values with the greatest differences 
noted when the source is far from the target region, i.e. for 
the N←Cy and N←CS configurations. 
Conclusions: Realistic modelling of atomic relaxation 
following nuclear decay is essential for producing the 
radiation spectra needed for the calculations of S-values.  
 
Keywords Auger-electron emitter; Monte Carlo simulation; S-
values; Nuclear medicine; 
 
References: 
[1] F Salvat, PENELOPE-2011; NEA 6416 
[2] N Falzone J Nucl Med 2015; 56(9): 1441 
[3] KF Eckerman and A Endo, MIRD Radionuclide Data and 
Decay Schemes 2008 
[4] B Lee et al. Comp Math Meth Med 2012; 651475 
 
135 
Range Verification with Ionoacoustics: simulations and 
measurements at a clinical proton synchro-cyclotron 
S. Lehrack   W. Assmann1, A. Maaß1, K. Baumann1, G. Dedes1, 
S. Reinhardt1, P. Thirolf1, G. Dollinger2, F. Vander Stappen3, 
J. Van de Walle3, S. Henrotin3, B. Reynders3, D. Bertrand3, 
D. Prieels3, K. Parodi1 
1 Department for Medical Physics, Ludwig-Maximilians-
Universität München, Am Coulombwall 1, 85748 Garching b. 
München, Germany 
2 Institute for Applied Physics and Instrumentation, 
Universität der Bundeswehr, Werner-Heisenberg-Weg 39, 
85577 Neubiberg, Germany 
3 IBA, 3 chemin du Cyclotron, 1348 Louvain-la-Neuve, Belgium 
 
Purpose: The local temperature increase induced by ion 
energy deposition in tissue creates an “ionoacoustic” 
ultrasound signal, particularly at the dose maximum (Bragg 
peak)[1-3]. This signal may be used for range verification in 
ion beam therapy in the future, which is still an important 
challenge for this irradiation modality. This approach has 
recently been revisited by several groups in simulations [4, 
5], and by our group in simulations and also in proof-of-
principle experiments with pulsed 20 MeV proton beams [6]. 
Here we present new simulations and first measurements of 
the ionoacoustic signal produced in water by proton beams 
accelerated up to energies of 227 MeV at a clinical synchro-
cyclotron. 
Material and Methods: In preparation of ionoacoustic 
experiments at clinically relevant energies, we extended our 
simulations from previously 20 MeV to beam energies of 120-
230 MeV. The propagation of ultrasound waves was simulated 
by the MATLAB toolbox k-Wave using Geant4 for calculations 
of the initial dose deposition. The corresponding 
experimental setup to measure the ionoacoustic signal 
consisted of a broadband hydrophone (500 Hz - 250 kHz) 
placed in a water phantom with protons entering through the 
water surface. We measured the transit time of the 
ionoacoustic signal from the Bragg peak to the hydrophone 
and varied this distance either by using different energies 
(227, 226 and 145 MeV) or by changing the detector position 
while using the maximum energy.  
Result: The simulations showed a distinct frequency shift of 
the ionoacoustic signal spectrum from a few MHz at 20 MeV 
from our previous experiments to about 100 kHz and below at 
proton beam energies above 120 MeV. At the new IBA 
synchro-cyclotron, we were able to measure ionoacoustic 
